The present invention relates to the fields of therapy and
drug delivery. More specifically, disclosed herein are therapeutic methods and pharmaceutical compositions for treating disorders of blood-tissue barrier-shielded organs that harbour substantive populations of post-mitotic neurons, such as the organs derived from
neural tube that include the
central nervous system and the eye. The disclosed methods and compositions involve localised administration into such organs of an
effector component that targets an
intracellular biological target, in combination with a
saponin component that enhances effective uptake of the
effector component into the cells and / or that enhances effective routing of the
effector component inside the cells where the
biological target is present. For example, the effector component can be an
oligonucleotide therapeutic that is targeting a
gene product associated with the disorder of the CNS and / or of the eye. Due to cellular uptake-stimulating and / or endosomal escape enhancing effects of the
saponin component, the presented herein neuropharmaceutical and ophthalmic compositions for the localised administration into the CNS and / or into the eye, respectively, can be formulated with lower concentrations of the effector component and / or at lower volumes, which confers safety-benefits to the neurons and to the comfort of the patient.